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based exclusion of ventilator-acquired
pneumonia to reduce antibiotic use
(VAPrapid-2): study protocol for a
randomised controlled trial’
Thomas P. Hellyer1*, Niall H. Anderson2, Jennie Parker3, Paul Dark4, Tina Van Den Broeck5, Suveer Singh6,
Ronan McMullan7, Ashley M. Agus8, Lydia M. Emerson9, Bronagh Blackwood9, Savita Gossain10, Tim S. Walsh11,
Gavin D. Perkins12, Andrew Conway Morris13, Daniel F. McAuley2,8,14 and A. John Simpson1Erratum
Unfortunately, the original version of this article [1]
contained an error. There are two references in the
text to the threshold for defining VAP as greater than
10^4 colony forming units/ml. These should read
greater OR EQUAL to 10^4 colony forming units/ml.
The error is in the abstract and in the intervention
sections.
In the abstract, please replace:
Patients with clinically suspected VAP undergo BAL
and VAP is confirmed by growth of a potential pathogen
at [>]104 colony forming units per millilitre (CFU/ml).
With the following correct version:
Patients with clinically suspected VAP undergo BAL
and VAP is confirmed by growth of a potential pathogen
at [≥]104 colony forming units per millilitre (CFU/ml).
In the Interventions, please replace:
VAP is confirmed by the widely used threshold of
growth of a potential pathogen at [>]104 colony forming
units per ml (CFU/ml)(13).
With the following correct version:
VAP is confirmed by the widely used threshold of
growth of a potential pathogen at [≥]104 colony forming
units per ml (CFU/ml)(13).
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